MXPA05011432A - Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. - Google Patents
Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.Info
- Publication number
- MXPA05011432A MXPA05011432A MXPA05011432A MXPA05011432A MXPA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A MX PA05011432 A MXPA05011432 A MX PA05011432A
- Authority
- MX
- Mexico
- Prior art keywords
- thrombin
- mopidamole
- treatment
- dipyridamole
- disorders caused
- Prior art date
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002768 dipyridamole Drugs 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 108090000190 Thrombin Proteins 0.000 title abstract 2
- 102000003790 Thrombin receptors Human genes 0.000 title abstract 2
- 108090000166 Thrombin receptors Proteins 0.000 title abstract 2
- 208000001435 Thromboembolism Diseases 0.000 title abstract 2
- 229960004072 thrombin Drugs 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46516803P | 2003-04-24 | 2003-04-24 | |
| PCT/EP2004/004097 WO2004093881A2 (en) | 2003-04-24 | 2004-04-17 | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05011432A true MXPA05011432A (es) | 2006-03-21 |
Family
ID=33311001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05011432A MXPA05011432A (es) | 2003-04-24 | 2004-04-17 | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20050014770A1 (https=) |
| EP (2) | EP1622621A2 (https=) |
| JP (1) | JP2006524203A (https=) |
| KR (1) | KR20060007034A (https=) |
| CN (1) | CN1812792A (https=) |
| AU (1) | AU2004231306A1 (https=) |
| BR (1) | BRPI0409796A (https=) |
| CA (1) | CA2523157A1 (https=) |
| MX (1) | MXPA05011432A (https=) |
| RU (1) | RU2005136383A (https=) |
| WO (1) | WO2004093881A2 (https=) |
| ZA (1) | ZA200508016B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US7064130B2 (en) * | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| US20090048173A1 (en) | 2004-05-13 | 2009-02-19 | Wolfgang Eisert | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors |
| WO2006045756A1 (en) * | 2004-10-25 | 2006-05-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| DE102005028168B3 (de) | 2005-06-17 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung |
| AR062057A1 (es) * | 2006-07-17 | 2008-10-15 | Boehringer Ingelheim Int | Uso de los inhibidores directos de la trombina |
| CL2007002067A1 (es) * | 2006-07-17 | 2008-01-25 | Boehringer Ingelheim Int | Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras. |
| CA2657266A1 (en) * | 2006-07-17 | 2008-01-24 | Boehringer Ingelheim International Gmbh | New indications for direct thrombin inhibitors in the cardiovascular field |
| WO2009080301A1 (en) * | 2007-12-21 | 2009-07-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke |
| RU2377990C1 (ru) * | 2008-07-23 | 2010-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов |
| CA2734809A1 (en) * | 2008-08-19 | 2010-02-25 | Boehringer Ingelheim International Gmbh | Dabigatran in tumour therapy |
| AR074108A1 (es) * | 2008-11-11 | 2010-12-22 | Boehringer Ingelheim Int | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina |
| US20130131088A1 (en) * | 2010-01-13 | 2013-05-23 | University Health Network | Treating cancer with statins and compounds having dipyridamole activity |
| KR20180074707A (ko) * | 2015-10-15 | 2018-07-03 | 모세 로고스니츠키 | 저 용량 경구 디피리다몰 조성물 및 이의 용도 |
| WO2019241793A1 (en) * | 2018-06-15 | 2019-12-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of detection of mechanically-activated platelet activation and uses thereof |
| US20260060965A1 (en) * | 2024-08-26 | 2026-03-05 | Research Institute at Nationwide Children’s Hospital | Modulating the acute foreign body reaction to reduce stenosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3031450A (en) | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| GB1051218A (https=) | 1963-03-09 | |||
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| DE3627423A1 (de) | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| DE4035961A1 (de) | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| EP1093814A1 (en) * | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| US6979462B1 (en) * | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| US20020048599A1 (en) | 2000-10-20 | 2002-04-25 | Thomas H. Mueller | Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation |
| HUP0304058A2 (hu) * | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| EP1250921A1 (en) | 2001-04-21 | 2002-10-23 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Fast disintegrating meloxicam tablet |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
| EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
| US20030180282A1 (en) * | 2002-03-25 | 2003-09-25 | Victor Serebruany | Method of treatment of thrombotic events |
| CA2496445A1 (en) * | 2002-08-14 | 2004-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors |
| CN1747734A (zh) * | 2003-02-07 | 2006-03-15 | 贝林格尔·英格海姆国际有限公司 | 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途 |
-
2004
- 2004-04-17 AU AU2004231306A patent/AU2004231306A1/en not_active Abandoned
- 2004-04-17 EP EP04728114A patent/EP1622621A2/en not_active Withdrawn
- 2004-04-17 EP EP09152218A patent/EP2062580A1/en not_active Withdrawn
- 2004-04-17 WO PCT/EP2004/004097 patent/WO2004093881A2/en not_active Ceased
- 2004-04-17 CN CNA200480017862XA patent/CN1812792A/zh active Pending
- 2004-04-17 BR BRPI0409796-3A patent/BRPI0409796A/pt not_active IP Right Cessation
- 2004-04-17 MX MXPA05011432A patent/MXPA05011432A/es not_active Application Discontinuation
- 2004-04-17 RU RU2005136383/14A patent/RU2005136383A/ru not_active Application Discontinuation
- 2004-04-17 JP JP2006505175A patent/JP2006524203A/ja active Pending
- 2004-04-17 KR KR1020057020187A patent/KR20060007034A/ko not_active Withdrawn
- 2004-04-17 CA CA002523157A patent/CA2523157A1/en not_active Abandoned
- 2004-04-22 US US10/830,294 patent/US20050014770A1/en not_active Abandoned
-
2005
- 2005-10-04 ZA ZA200508016A patent/ZA200508016B/en unknown
-
2006
- 2006-09-01 US US11/469,503 patent/US20070105753A1/en not_active Abandoned
-
2009
- 2009-04-03 US US12/418,001 patent/US20090192123A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005136383A (ru) | 2007-06-10 |
| KR20060007034A (ko) | 2006-01-23 |
| ZA200508016B (en) | 2007-03-28 |
| WO2004093881A3 (en) | 2005-06-16 |
| US20070105753A1 (en) | 2007-05-10 |
| BRPI0409796A (pt) | 2006-05-30 |
| EP1622621A2 (en) | 2006-02-08 |
| CA2523157A1 (en) | 2004-11-04 |
| JP2006524203A (ja) | 2006-10-26 |
| CN1812792A (zh) | 2006-08-02 |
| AU2004231306A1 (en) | 2004-11-04 |
| US20050014770A1 (en) | 2005-01-20 |
| EP2062580A1 (en) | 2009-05-27 |
| US20090192123A1 (en) | 2009-07-30 |
| WO2004093881A2 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05011432A (es) | Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina. | |
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| EA200400982A1 (ru) | Способы лечения пациентов, страдающих от нарушения движений | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| BR0107732A (pt) | Método para prevenir ou tratar uma doença | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
| TN2009000137A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| WO2005051429A3 (en) | Targeted conjugates with a modified saccharide linker | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| JP2004537500A5 (https=) | ||
| PL377715A1 (pl) | Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej | |
| MX2023000610A (es) | Inhibidor de trpv4 como agente terapeutico para enfermedades oculares. | |
| AU2001266289A1 (en) | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury | |
| ATE392901T1 (de) | Mucuna pruriens und extrakte daraus zur behandlung von neurologischen erkrankungen | |
| WO2006002096A3 (en) | Low doses of l-citrulline for treating diseases | |
| WO2004069254A3 (en) | Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |